Winton Gibbons

My background merges industry, consulting, and financial services, predominantly for innovative clinical diagnostic, life science, and therapeutic companies. These have been based on biotechnology, nanotechnology, and microfluidics, as well as novel biomarkers. This experience enables me to contribute highly as a senior leader or consultant.

Most recently, I was Senior Vice President for Corporate Development at Agena Bioscience, which makes genetic testing equipment. For the clinical diagnostic and life science fields, I have also been a senior leader at Roche, Merck, Biosite, Siloam Bioscience, and Nanosphere.

In financial services, I was the group head for healthcare equity research, sell-side analyst, and a principal with William Blair Read more

My background merges industry, consulting, and financial services, predominantly for innovative clinical diagnostic, life science, and therapeutic companies. These have been based on biotechnology, nanotechnology, and microfluidics, as well as novel biomarkers. This experience enables me to contribute highly as a senior leader or consultant.

Most recently, I was Senior Vice President for Corporate Development at Agena Bioscience, which makes genetic testing equipment. For the clinical diagnostic and life science fields, I have also been a senior leader at Roche, Merck, Biosite, Siloam Bioscience, and Nanosphere.

In financial services, I was the group head for healthcare equity research, sell-side analyst, and a principal with William Blair & Company, an investment bank in Chicago.

For McKinsey & Company, I held manager and consultant positions.

I have an M.B.A. in finance and strategic policy from the University of Chicago, and a Bachelor of Science in chemistry from Duke University.

-----

Foremost abilities

• Strategy & Business Development
• Market assessment & research
• Biomarkers & diagnostics
• Marketing & sales
• Quantitative research & analysis

Fields

• Biomarkers and diagnostics: protein biomarkers and other immunoassays, molecular diagnostics (companion diagnostics, human genetics, pharmacogenomics, infectious diseases, and other nucleic acid testing), microarrays, glucose monitoring and other diagnostic products for diabetes, and point-of-care (POC) testing

• Financial service and investment experience: sell-side equity research, evaluation of high-growth and emerging-growth companies, stock picking, fundamental research and quantitative modeling, technology and market opportunity assessment, and equity and new venture funding

Two typical engagement types. 4 to 8 week’s, with project fee. Ad hoc hourly consulting or functional activity, e.g., business development.